 The Street seems uncommonly skeptical about the long-term merits of IFFs merger with DuPonts Nutrition and Bioscience business, with the shares trading below both near- and long-term fair values. Cross-selling synergies may take longer to appear, and may be more dependent upon RD, but NB does bring exposure to more attractive markets like plant protein and probioticscultures. 